StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Research analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

InspireMD Price Performance

Shares of NYSE NSPR opened at $2.32 on Friday. The stock’s fifty day moving average price is $2.78 and its two-hundred day moving average price is $2.74. InspireMD has a one year low of $1.87 and a one year high of $3.80. The firm has a market cap of $71.07 million, a price-to-earnings ratio of -3.09 and a beta of 0.74.

Institutional Trading of InspireMD

Several large investors have recently modified their holdings of NSPR. Affiance Financial LLC grew its holdings in shares of InspireMD by 2.9% during the 4th quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after purchasing an additional 5,376 shares in the last quarter. Legato Capital Management LLC acquired a new stake in shares of InspireMD during the 4th quarter worth $47,000. Essex Investment Management Co. LLC acquired a new stake in shares of InspireMD during the 4th quarter worth $191,000. Renaissance Technologies LLC acquired a new stake in shares of InspireMD during the 4th quarter worth $27,000. Finally, Northern Trust Corp lifted its position in shares of InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after buying an additional 24,452 shares during the last quarter. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.